As for other well-established driver alterations, HER2 mutation and amplification are less common in SCC compared to lung adenocarcinoma [136], while the prevalence of NTRK1/2/3 gene fusions do not vary across histologies [19]. Here, ERBB2 is linked to lung adenocarcinoma.